HDR-mediated gene editing preserves regulation

Gene therapy can be problematic if the therapeutic gene is constitutively expressed. Using a combined knockout and knockin gene editing strategy, correction of human RAG1 in HSPCs from patients has restored immune function in xenotransplanted mice modelling RAG1 deficiency.

By: Gorm Palmgren - Feb. 8, 2024
News

#CRISPRMED24

Mutations in recombination activating gene 1 (RAG1) can cause severe combined immunodeficiency, but as the gene is tightly regulated, constitutive expression after gene therapy raises concerns for immune dysregulation.

Now, researchers at the San Raffaele-Telethon Institute for Gene Therapy (SR-Tiget) in Milan have developed a CRISPR-Cas9 HDR-mediated approach for integrating a corrective sequence into the human RAG1.

In-frame insertion into exon 2 drove physiologic human RAG1 expression and activity in HSPCs from patients with high gene correction efficiency. When these cells were xenotransplanted into immunodeficient Rag1–/– mice, they led to improved B cell production and overcame the T cell differentiation block.

Anna Villa and Maria Carmina Castiello, both at SR-Tiget, were senior and first authors of the study published yesterday in Science Translational Medicine. You can read it here.

To get more of the CRISPR Medicine News delivered to your inbox, sign up to the free weekly CMN Newsletter here.

Tags

HashtagArticleHashtagCMN BriefsHashtagNews

News: HDR-mediated gene editing preserves regulation
News: HDR-mediated gene editing preserves regulation
CLINICAL TRIALS
Renal Cell Carcinoma, RCC, (NCT06245915)
Sponsors:
Arsenal Biosciences, Inc.
IndicatorIndicator
IND Enabling
Phase I
Phase II
Phase III
Solid Tumors, (NCT06237881)
Sponsors:
M.D. Anderson Cancer Center
IndicatorIndicator
IND Enabling
Phase I
Phase II
Phase III
Breast Cancer, BC, (NCT05812326)
Sponsors:
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
IndicatorIndicator
IND Enabling
Phase I
Phase II
Phase III
View all clinical trials
close
Search CRISPR Medicine